4.6 Letter

The histone deacetylase inhibitor UCL67022 has potent activity in multiple myeloma and non-Hodgkin lymphoma pre-clinical models

Journal

BRITISH JOURNAL OF HAEMATOLOGY
Volume 163, Issue 1, Pages 135-139

Publisher

WILEY
DOI: 10.1111/bjh.12456

Keywords

new drug development; lymphomas; myeloma

Categories

Funding

  1. Biotechnology and Biological Sciences Research Council Funding Source: Medline

Ask authors/readers for more resources

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.6
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available